The low down on low-dose endocrine disruptors. by Schmidt, C W
Endocrine-disrupting chemicals are among the
most complex environmental health threats
known today. By mimicking natural hormones
such as estrogen and testosterone, these chemi-
cals can interact with the body’s endocrine sys-
tem and exert toxic effects that may lead to
reproductive and developmental abnormalities
or cancer. In October 2000, the National
Toxicology Program (NTP) and the NIEHS
convened an independent panel of experts from
academia, government, and industry to evalu-
ate the evidence for low-dose effects and
dose–response relationships for endocrine dis-
ruptors. “This was a highly experienced panel,”
says NIEHS toxicologist Ron Melnick, chair of
the panel organizing committee. “Members
had broad experience in areas including molec-
ular biology, reproductive and developmental
toxicology, and statistical and mathematical
modeling. Many of them were professors and
department chairs from some of the leading
biomedical research institutes in the country.”
The panel’s conclusions were released 14 May
2001 in the National Toxicology Program’s
Report of the Endocrine Disruptors Low-Dose
Peer Review. 
Low-Level Exposures and Public Health
The peer review panel was assembled at the
request of the U.S. Environmental Protection
Agency (EPA), which is now validating test
methods to screen 87,000 chemicals for hor-
monal effects [see EHP 107:A458–A460
(1999)]. In assessing public health risks from
endocrine disruptors, the EPA faces some diffi-
cult challenges. Unlike traditional toxicology,
in which the dose always starts out from zero,
exposure to endocrine disruptors adds incre-
mentally to what’s already present in the body
as naturally occurring hormone. In some
instances, the natural hormone is associated
with a certain degree of risk. Estrogen, for
example, is known to cause breast cancer in
humans. “The question is, what happens to the
risk when exposure to endocrine disruptors dri-
ves hormone levels higher than what they nor-
mally would be?” explains George Lucier, chair
of the peer review panel. 
For this specific review, the EPA’s main
concern was to resolve questions concerning
the effects of low-dose exposures. Humans are
usually exposed to these chemicals at extremely
low levels. Yet the standard tests used by the
EPA to evaluate reproductive and developmen-
tal toxicity (contained in the agency’s August
1998 document Health Effects Test Guidelines
OPPTS 870.3800: Reproduction and Fertility
Effects) often fail to consider the impact of
doses lower than those producing no evidence
of overt adverse effects, described as the no-
observed-effect level, or NOEL. For this
review, the panel evaluated evidence of biologic
changes due to exposure to endocrine disrup-
tors at doses below the NOEL. Melnick says
biologic changes were emphasized over adverse
effects because in many cases the long-term
consequences of altered endocrine function
have yet to be fully characterized. 
The organizing committee identified 59
studies for review. These studies investigated
chemicals with a wide range of hormonal prop-
erties, including bisphenol A, diethylstilbestrol
(DES), ethinyl estradiol, nonylphenol, octyl-
phenol, genistein, methoxyclor, 17β-estradiol,
and vinclozolin. Melnick says the main criteri-
on for study inclusion was an “evaluation of
multiple doses extending reasonably far into the
low-dose region.” The raw data from 39 of the
studies underwent statistical reanalysis by a sub-
group of experienced, impartial statisticians. 
“This was an incredibly stringent review,”
says Lynn Goldman, professor at The Johns
Hopkins University in Baltimore, Maryland,
and former assistant administrator at the EPA.
“In some cases, we found the initial statistics
were not properly conducted. Overall, the
review process was much more intensive than
anything I’ve seen for publication in a journal,”
she says. “There was complete transparency at
every step of the way for all the investigators
and the public. Comment from industry and
environmental groups was always welcome.” 
Nonmonotonic Dose Response 
A key outcome of the review was verification
that some endocrine disruptors exhibit
dose–response relationships described as non-
monotonic, meaning that within a certain
dose range, a chemical’s effects on a given end
point actually become greater as the dose is
reduced. The dose–response curves can be
shaped like a U, with a high response at both
low and high levels of exposure, or like an
inverted U, with the greatest response at inter-
mediate dose levels. According to Frederick
vom Saal, a professor in the Division of
Biological Sciences at the University of
Missouri in Columbia, nonmonotonic curves
challenge the EPA’s standard assumption of
linear or threshold dose responses, which
holds that toxic effects always lessen as the
dose is reduced toward zero.
One chemical found to exhibit non-
monotonic relationships is bisphenol A, an
estrogenic plastic used in products including
baby bottles and water cooler jugs. Due in
part to its high visibility in the marketplace,
bisphenol A was the subject of its own sepa-
rate subpanel review. Studies conducted by
Vom Saal showed that low-dose exposure to
bisphenol A in mice produces prostate
enlargement with an inverted U–shaped
dose–response curve. These findings have
helped fuel the concern of environmentalists
that exposures to the chemical might enhance
the risk of prostate cancer, in addition to other
illnesses.
Vom Saal wasn’t overly surprised by his
results. “Any endocrinologist will
tell you that hormone receptors
are up-regulated [stimulated] at
low doses and down-regulated at
high doses,” he says. “In fact, in
clinical therapy you can shut
down a hormonal system simply
by treating with high levels of hor-
mone.”
Although Vom Saal’s results were
shown to be credible under the
panel’s statistical reanalysis,
they were found not to be
reproduced in other,
equally credible studies.
Interstudy differences in
animal strain, diet, dosing
regimens, and even housing
conditions were all offered
as possible explanations for
the discrepancy. 
Based on the incon-
sistency of the data, the
panelists were not per-
suaded that a low-dose
effect of bisphenol A
has been conclusively
established as a general
or reproducible finding,
an admission seized on
by the plastics indus-
try, which insists low-
dose exposure to the
chemical is safe. 
“I believe Dr. Vom
Saal is convinced of his find-
ings, but he has not con-
vinced his scientific peers,”
says Paul Foster, program
director of endocrine, repro-
ductive, and developmental
toxicology at the CIIT
Centers for Health Research
in Research Triangle Park,
North Carolina, a research
organization sponsored by
industry. “The inability to
reproduce the findings of an
increase in prostate weight
[or any pathological responses
associated with this weight
change] in mice [of differ-
ent strains] and rats indi-
cates that this change is
not robust, nor a uni-
versal phenomenon
likely to have impli-
cations for human health risk assessment.”
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PBut Lucier cautions that the panel’s state-
ment on bisphenol A shouldn’t be taken out of
context. Vom Saal’s data are of high quality, he
says, and the evidence for a low-dose effect
can’t be discounted. Taken as a whole, the data
for bisphenol A and other chemicals reviewed
by the panel indicate nonmonotonic, linear,
and even threshold responses are all possible
outcomes of low-dose endocrine disruptor
exposure. The fact that biologic effects were
noted in the low-dose region below the NOEL
for some data sets, he says, suggests that the
EPA should review its current testing protocols
to see if changes are required.
Multigenerational Studies at Issue
Another of the panel’s most important conclu-
sions concerns the ability of EPA testing proto-
cols to accurately evaluate reproductive and
developmental effects. Experts suggest that
endocrine disruptors pose the greatest risk dur-
ing fetal development, which is regulated by
hormones at specific levels. Hormonal alter-
ations due to maternal exposure in pregnancy
could lead to effects such as reduced cognitive
function or cancer that might not be evident for
months, even years. The EPA’s current method
for evaluating these effects is the multigenera-
tional reproduction study, in which animals are
exposed at critical periods of sexual differentia-
tion and their second-generation offspring eval-
uated at 21 days after birth. 
One of the panel’s main concerns is that
the 21-day period of evaluation is too short.
The risk of missing developmental effects if
studies are terminated too soon is exemplified
by the research of Retha Newbold, a biologist
with the NIEHS Laboratory of Toxicology
who has studied DES, an estrogenic hormone
once used to prevent miscarriages that wound
up causing cancer in the adult daughters of
treated women. Newbold has performed stud-
ies in which mice were exposed at 1–5 days of
age to DES and then allowed to grow for 18
months. In her studies, Newbold found signifi-
cant increases in uterine tumors among the
treated mice, which she says wouldn’t have
been detected with the standard multigenera-
tional assay. Uterine tumors were also observed
in similar studies with genistein, which is an
estrogenic component of soybeans.
Echoing the opinion of the panel on this
issue, Goldman says, “I think we’re going to
have to revisit the standard multigenerational
test to ensure that the end points, the animal
models, and the ages of evaluation are appropri-
ate for assessing development effects from
endocrine disruptor exposure.” 
Although evidence of low-dose biologic
effects was confirmed by the review, panel
members were careful to note that the toxico-
logic significance of these findings is unknown.
“Take the issue of prostate enlargement with
bisphenol A exposure,” says Goldman. “I don’t
think we understand the significance of that
finding. Where do we go with this? How is it
going to impact the way in which we regulate
bisphenol A? This is a new area, and we don’t
have many precedents to rely on. We just don’t
have years of decision making based on this
type of data.” 
The panel’s conclusions raise serious ques-
tions about the extent to which current EPA
testing protocols are able to accurately evaluate
endocrine-disrupting effects. The panel notes
that extended dose ranges are not typically
used, and end points such as cancer and neu-
rodevelopmental effects are rarely considered in
multigenerational assays. No specific recom-
mendations as to how the process might be
improved were made. But the panel’s report
clearly states that the EPA will need to revisit
current test methods for evaluating reproduc-
tive and developmental toxicity to determine if
changes are needed for endocrine-disrupting
agents. –Charles W. Schmidt
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New Mouse Genomics Consortium
The NIEHS announced on 3 May 2001 that five research centers comprising the
Comparative Mouse Genomics Centers Consortium have been selected to develop
mouse lines with genetic variations that may be key to understanding the effects
of environmental stressors on the body. The mice, protocols, assays, assessment
criteria, and data generated through projects using them will be made available
to scientists around the world to help determine how such gene variations make
some individuals more sensitive or resistant to environmental exposures. The
centers will develop new mouse models to study the processes that repair envi-
ronment-damaged DNA and regulate cell life cycles. The consortium is part of the
Environmental Genome Project, begun by the NIEHS in late 1997 to identify genes
and alleles that affect individual response to environmental exposures.
Pooling the established resources of this diverse group of scientists will ease
the transfer of emerging materials, data, and technology and is intended to
encourage discoveries that will help scientists better understand the complex
interaction between the environment and human health. “This is a very compre-
hensive program, with over ninety investigators based at the centers,” says José
Velazquez, the NIEHS program director for the centers. Information gathered
through research at these centers could not only help scientists better predict
health risks to sensitive individuals, but could also help policy makers draft public
and environmental health regulations that have a more scientific basis and that
are more cost-effective to better protect those affected.
The centers will be governed by a steering committee responsible for provid-
ing general direction and guidance to consortium programs. A main focus of the
centers will be to develop technologies such as three-dimensional protein imag-
ing, which could be used to predict the function of the variations; whole-mouse
imaging using PET scanning, which could more quickly detect tumor formation;
microarray gene expression analysis; proteomics; and a whole new suite of bioin-
formatics tools to integrate the emerging data. The consortium will also explore
modeling strategies, including in vitro DNA variant assessment (which is used to
determine which allelic variants to model) and construction of transgenic vectors,
using state-of-the-art molecular biological approaches for gene targeting.
One major goal of this project, says Velazquez, will be the launch of a new
bioinformatics Web site in late 2001 that will integrate the available gene and
protein data for approximately 200 genes that function to repair environmental
damage and regulate cell life cycles. In addition, the consortium’s Web site, which
should be available to the public by November 2001, will display the models
under development and bioinformatics tools to mine the available data. Both
sites will be available through the Environmental Genome Project home page,
located at http://www.niehs.nih.gov/envgenom/home.htm.
The participating centers are The Albert Einstein College of Medicine of
Yeshiva University (the Bronx, New York), the University of Washington
(Seattle), the University of Cincinnati (Ohio), the University of Texas Health
Science Center at San Antonio, and the University of Texas M. D. Anderson
Cancer Center (Smithville). Over the next five years, the centers will receive
$5–6 million in grants per year. Each center will focus on separate sets of genes
determined to play a role in aging and the development of cancer and other
diseases. –Erin E. Dooley